

Allergy Therapeutics PLC

Notice of Annual General Meeting

Thursday 29 January 2026

Directors:

Peter Jensen O.B.E. (Non-Executive Chairman)

Manuel Llobet (Chief Executive Officer)

Dr. Shaun Furlong (Chief Financial Officer)

David Ball (Non-Executive Director)

Cheryl MacDiarmid (Non-Executive Director)

Tunde Otulana (Non-Executive Director)

Anthony Parker (Non-Executive Director)

Zheqing (Simon) Shen (Non-Executive Director)

Registered Office:

Dominion Way

Worthing

West Sussex BN14 8SA

THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt as to what action you should take, you are recommended to seek your own financial advice from your stockbroker or other independent adviser authorised under the Financial Services and Markets Act 2000.

If you have sold or transferred all of your shares in Allergy Therapeutics plc, please forward this document, together with the accompanying documents, as soon as possible either to the purchaser or transferee or to the person who arranged the sale or transfer so they can pass these documents to the person who now holds the shares.

Annual General Meeting

6 January 2026

Dear Shareholder,

2025 Annual General Meeting

I am writing to provide you with details of the arrangements we have made for the Annual General Meeting ("AGM") of Allergy Therapeutics plc (the "Company"), which will be held at the offices of Cooley (UK) LLP at 22 Bishopsgate, London EC2N 4BQ on 29 January 2026 at 11:00 a.m.. The notice convening the AGM is set out on pages 5 to 8 of this document and more information on the AGM and resolutions to be considered at the AGM is set out below.

Voting on the business of the AGM will be conducted by way of a poll, to reflect the proxy voting instructions received. Our registrars must receive your proxy appointment by 11:00 a.m. on 27 January 2026.

Shareholder questions

We welcome your questions on the business of the AGM and encourage you to send these questions to cosec@allergytherapeutics.com in good time ahead of the AGM.

Action to be taken

Please register your proxy vote no later than 11:00 a.m. on 27 January 2026 online via the Investor Centre app or at <https://uk.investorcentre.mpms.mufg.com/>, or you may request a paper proxy form from our registrar, MUFG Corporate Markets by calling by calling 0371 664 0300 (if calling from the United Kingdom), or +44 371 664 0300 (if calling from outside of the United Kingdom), or emailing shareholderenquiries@cm.mpms.mufg.com. Shareholders who are CREST members may submit their CREST Proxy Instructions online via the CREST electronic appointment service. Further details of how to register your proxy vote are contained within the notes to the Notice of AGM. The return of a form of proxy will not preclude a shareholder from attending and voting at the AGM if he/she so wishes. You are urged to appoint the chair of the AGM as your proxy, with voting instructions, in advance of the AGM.

Persons intending to attend the AGM in person will need a QR code to access the AGM venue. Such QR code will need to be displayed on a smartphone or similar device. A QR code will be able to be obtained in advance by emailing the Registrars at meetingsadvisoryteam@cm.mpms.mufg.com with your full name and email address. Persons who have not obtained a QR code in advance will be able to obtain one at the AGM venue.

Resolutions to be proposed at the AGM

Resolutions 1 to 10 deal with the ordinary business that normally takes place at the AGM and Resolutions 11 to 13 relate to special business that normally takes place at the AGM.

Resolution 1 – Approval of 2025 Accounts

The Directors are required by the Companies Act 2006 (the "Companies Act") to lay before the Company in general meeting copies of the Directors' reports, the independent auditor's report and the audited consolidated financial statements of the Company in respect of each financial year.

Resolution 1 is an ordinary resolution to receive the Company's annual report and accounts for the year ended 30 June 2025 (the "2025 Accounts"), including the Directors' report, the consolidated financial statements and the auditors' report of the Company for the year ended 30 June 2025.

Resolution 2 – Approval of Directors' Remuneration Report

Resolution 2 is an ordinary resolution to approve the Directors' remuneration report, as set out on pages 55 to 62 of the 2025 Accounts, in respect of the year ended 30 June 2025. The Directors' remuneration report sets out details of each Director's remuneration during the financial year ended 30 June 2025. In

accordance with the relevant regulations, the resolution is an advisory vote and non-binding and does not affect the remuneration already paid to any Director.

Resolutions 3 to 4 – The election of Directors

The Articles allow the Company to appoint, by ordinary resolution at a general meeting, any individual recommended by the Board for election as a director. The Board has identified Helge Weiner-Trapness and Lawrence Allen Wang as candidates whose skills and experience would add significant value to the Board, and who each bring decades of expertise in their respective fields. The Board believes these appointments will directly support the Company's current exploration of a potential dual primary listing on the Hong Kong Stock Exchange, alongside its existing listing on the London Stock Exchange's AIM market, and the ambition to expand Allergy Therapeutics' presence in Asia and become a global leader in allergy treatments.

Accordingly, the Board proposes that shareholders elect Helge Weiner-Trapness and Lawrence Allen Wang as Directors at the AGM under article 69 of the Articles.

Brief biographies of both proposed directors are below.

Helge Weiner-Trapness – Executive Director and Chief Strategy Officer

Until 2025, Mr Weiner-Trapness held the role of Vice Chairman, Global Banking, at HSBC, one of the world's largest financial organisations which is dual-listed on the London Stock Exchange and the Hong Kong Stock Exchange. Prior to this, he was a Founding Partner of Quintus Partners, an independent financial advisory firm offering investment banking, strategic advisory and capital raising, particularly in the US and Asia. With earlier, senior positions at Barclays Bank, Asia Pacific Land, JP Morgan Securities and Goldman Sachs, Mr Weiner-Trapness brings more than 30 years of experience across some of the world's biggest investment banks in the US and Asia.

In the newly created role of Chief Strategy Officer, Mr Weiner-Trapness will drive the Company's long-term growth strategy, including corporate development, partnership strategy and portfolio prioritisation, as Allergy Therapeutics advances its next-generation pipeline and explores opportunities to deliver on its global ambitions.

Lawrence Allen Wang – Non-Executive Director

Lawrence Allen Wang is the Chief Financial Officer of Adicon (HKG: 9860) one of China's leading independent clinical laboratory service providers. Mr Wang led and executed the company's \$88 million share financing in 2020, bringing in an international, blue-chip investor syndicate and, in 2023, successfully listed the company on the Hong Kong Stock Exchange. Later that year the company qualified for entry into the Hong Kong Stock Exchange's Stock Connect mutual market access programme, that links the Hong Kong Stock Exchange with Mainland China's two main exchanges. Mr Wang has more than 20 years of healthcare and investment experience. He qualified as a Doctor of Medicine from Boston University School of Medicine in 2003 and has an MBA from MIT Sloan School of Management.

Resolutions 5 to 6 – The election of Directors

The Articles contain standard provisions with respect to the retirement of Directors (i) by rotation and (ii) who have been appointed by the Board since the previous annual general meeting. In addition, the Articles require that one-third of the Directors (or, if the number of Directors is not an integral multiple of three, the number nearest to but not greater than one-third) shall retire from office at each annual general meeting.

The Board has selected Tunde Otulana and Cheryl MacDiarmid to retire by rotation at the AGM in compliance with the Articles. The shareholders are being asked to vote on their proposed re-elections at this AGM under article 73 of the Articles.

Resolution 7 – The re-election of Peter Jensen O.B.E. as Director

The Quoted Companies Alliance (QCA) Corporate Governance Code (the “**QCA Code**”) provides that any non-executive directors should be independent to be able to provide appropriate oversight and to perform their role. The QCA Code also provides that whilst concurrent tenure with the Board for more than nine years does not automatically taint independence, it does present a presumption to be rebutted. The Board is able to exercise its own judgment as to the independence of its Directors and determine its own mechanisms to assess independence and rebut the presumption. Consequently, the Board has agreed that it is good practice for any such Director to be re-elected on an annual basis.

Peter Jensen O.B.E. will retire as a Director at the AGM and has offered himself for re-election pursuant to Resolution 7. Mr Jensen has served for more than nine years on the Board and, during this time, the Board has received significant benefit from his expertise. The Board considers that the Chairman continues to perform his role effectively. The Board therefore concluded that Peter Jensen O.B.E. should continue in his role as Chairman. The independent Non-Executive Directors will review the position again in advance of the Company’s annual general meeting in 2026. Accordingly, the Board recommends that shareholders vote in favour of this resolution.

Resolutions 8 and 9 – Reappointment and remuneration of the auditor

On the recommendation of the Audit and Risk Committee, the Board proposes the reappointment of BDO LLP as the Company’s auditor for the financial year ending 30 June 2026.

Resolution 9 authorises the Audit and Risk Committee, on behalf of the Board, to determine and agree the auditor’s remuneration.

Resolution 10 – Authority to allot shares

The Companies Act provides that Directors must be authorised before they can allot, or grant options over, new shares. That authority has to be given by ordinary resolution. The Companies Act also provides that any new shares issued for cash must first be offered *pro-rata* to existing shareholders unless the statutory pre-emption procedure is disapplied by special resolution.

In line with the guidance issued by the Investment Association in 2023, the authority to allot shares contained in sub-paragraph 10.1 of Resolution 10 will, if passed, authorise the Directors to allot shares or grant rights to subscribe for or to convert any security into such shares in the Company up to a maximum nominal amount of £2,250,480. This amount represents approximately one-third of the total issued share capital of the Company (assuming that the authorities obtained at the general meeting of the Company held on 29 December 2025 (the “**December 2025 General Meeting**”) to allot up to an aggregate nominal amount of £610,000 of ordinary shares in connection with a Potential Equity Raise (as defined in the circular to shareholders and notice of general meeting dated 12 December 2025) are utilised in full, notwithstanding that no shares have yet been issued under that authority). The authority to allot shares contained in sub-paragraph 10.2 of Resolution 10 will, if passed, authorise the Directors to allot shares (including the shares and rights referred to in sub-paragraph 10.1) up to a maximum nominal amount of £4,500,960 in connection with a pre-emptive offer to existing shareholders. This amount represents approximately two-thirds of the total issued share capital of the Company (assuming that the authorities obtained at the December 2025 General Meeting to allot up to an aggregate nominal amount of £610,000 of ordinary shares in connection with a Potential Equity Raise are utilised in full, notwithstanding that no shares have yet been issued under that authority). The authorities in Resolution 10 will expire at the next annual general meeting of the Company or 16 March 2027, whichever occurs first.

Resolutions 11 and 12 – Disapplication of pre-emption rights

Under section 561 of the Companies Act, if the Directors wish to allot any equity securities for cash (other than in connection with any employee share scheme) they must offer them to existing shareholders in the first instance in proportion to their holdings. This is called pre-emption rights. Resolution 11 will, in line with the latest institutional shareholder guidelines, including the revised Statement of Principles published by the Pre-Emption Group in November 2022 (the “**2022 Statement of Principles**”), give the Directors the authority to allot equity securities for cash without first being required to offer such shares to existing shareholders for a period expiring at the conclusion of the next annual general meeting of the Company or 16 March 2027, whichever occurs first.

If approved, Resolution 11, which is proposed as a special resolution and follows the Pre-Emption Group’s template resolution, will empower the Directors, in accordance with the 2022 Statement of Principles, to issue shares in connection with a rights issue or other pre-emptive offer and otherwise to issue shares and/or sell treasury shares for cash: (A) for general corporate purposes (under sub-paragraph 11.2 of the resolution), up to a maximum nominal amount of £675,144 (representing approximately 10% of the issued share capital of the Company (assuming that the authorities obtained at the December 2025 General Meeting to disapply pre-emption rights in respect of the allotment of up to an aggregate nominal amount of £610,000.00 of ordinary shares in connection with a Potential Equity Raise are utilised in full, notwithstanding that no shares have yet been issued under that authority); and (B) for the purposes of making a follow-on offer to existing shareholders (under sub-paragraph 11.3 of the resolution and as described in the 2022 Statement of Principles), up to an additional aggregate amount equal to 20% of any allotment under sub-paragraph 11.2 of the resolution. The maximum additional nominal amount that could be issued under sub-paragraph 11.3 of the resolution (based on the authority under sub-paragraph 11.2 being used in full) is £135,029 (representing approximately 2% of the issued share capital of the Company, (assuming that the authorities obtained at the December 2025 General Meeting to disapply pre-emption rights in respect of the allotment of up to an aggregate nominal amount of £610,000.00 of ordinary shares in connection with a Potential Equity Raise are utilised in full, notwithstanding that no shares have yet been issued under that authority)).

Resolution 12 requests further shareholder approval, by way of a separate special resolution in line with the best practice guidance issued by the Pre-Emption Group, for the Directors to allot equity securities and/or sell treasury shares for cash without first being required to offer such securities to existing shareholders. The resolution follows the Pre-Emption Group’s template resolution and reflects the 2022 Statement of Principles.

The authority granted by this resolution, if passed, will be limited to the allotment of equity securities and the sale of treasury shares for cash: (A) under sub-paragraph 12.1 of the resolution, up to an aggregate nominal value of £675,144 (representing approximately 10% of the issued share capital of the Company (assuming that the authorities obtained at the December 2025 General Meeting to disapply pre-emption rights in respect of the allotment of up to an aggregate nominal amount of £610,000 of ordinary shares in connection with a Potential Equity Raise are utilised in full, notwithstanding that no shares have yet been issued under that authority), to be used only in connection with an acquisition or other capital investment of a kind contemplated by the 2022 Statement of Principles, and which is announced contemporaneously with the allotment, or has taken place in the preceding 12-month period and is disclosed in the announcement of the allotment; and (B) under sub-paragraph 12.2 of the resolution, up to an additional aggregate amount equal to 20% of any allotment under sub-paragraph 12.1 of the resolution, for the purposes of making a follow-on offer to existing shareholders as described in the 2022 Statement of Principles. The maximum additional nominal amount that could be issued under sub-paragraph 12.2 of the resolution (based on the authority under sub-paragraph 12.1 being used in full) is £135,029 (representing approximately 2% of the issued share capital of the Company (assuming that the authorities obtained at the December 2025 General Meeting to disapply pre-emption rights in respect of the allotment of up to an aggregate nominal amount of £610,000 of ordinary shares in connection with a Potential Equity Raise are utilised in full, notwithstanding that no shares have yet been issued

under that authority). The authority granted by this resolution would be in addition to the general disapplication of pre-emption rights under Resolution 11.

The Directors have no present intention of exercising the authorities under Resolutions 11 and 12. However, if they do exercise these authorities, they intend to follow best practice as regards their use, including (i) following the shareholder protections in Part 2B of the 2022 Statement of Principles and (ii) in respect of any follow-on offer, following the expected features set out in paragraph 3 of Part 2B of the 2022 Statement of Principles.

The proposed authorities under Resolutions 11 and 12 will expire at the conclusion of the next annual general meeting of the Company or 16 March 2027, whichever occurs first.

The new authorities are separate to the authorities that were obtained at the December 2025 General Meeting in connection with the Potential Equity Raise, and are being sought so as to maintain flexibility in the financing of the Company and to give the Directors the opportunity to take advantage of business opportunities as they arise. The Directors remain committed to growing the Company both organically and through acquisitions and to review potential acquisitions as opportunities arise. In addition to funding acquisitions through the issue of shares, the authorities will enable the Directors to raise additional working capital by way of a placing. It is the Directors' intention to seek renewal of these authorities annually.

Resolution 13 – Amendment of Articles

The Board is seeking shareholder approval to amend the Articles (the **"Amended Articles"**).

It is proposed that the aggregate remuneration cap for Non-Executive Directors, as set out in Article 78 of the Articles, be increased from £300,000 to £400,000 per annum, to ensure that the Non-Executive Directors remain appropriately remunerated for their services and to take into account the increased size of the Board since the limit was last reviewed.

The Amended Articles will also facilitate the potential dual listing of the Company's shares on the Hong Kong Stock Exchange, which was announced on 6 November 2025 and which is expected to occur in the first half of 2026 (the **"Hong Kong Listing"**). The amendments are necessary so the Company can establish and maintain a branch register in Hong Kong, and to enable the Company to comply with the core shareholder protection standards as set out in Appendix 3 to the Hong Kong Listing Rules.

Under the Amended Articles, votes cast by a shareholder shall not be counted where the Company is aware that the Hong Kong Listing Rules require that shareholder to abstain or vote in a particular way for a resolution and that shareholder has voted in contravention of that requirement. Articles do not put in place any additional restrictions on the voting rights of a shareholder that are not already provided for under the Hong Kong Listing Rules.

Due to the requirements of the Hong Kong Listing Rules and Hong Kong Stock Exchange listing application process, the amendments to the Articles, if approved by shareholders, will take effect immediately following the AGM and are not conditional on completion of the Hong Kong Listing.

The Hong Kong Listing remains subject to review and approval by the Hong Kong Stock Exchange and the Securities and Futures Commission of Hong Kong, and there is no guarantee that the Company will proceed with the Hong Kong Listing.

The Amended Articles, marked to show all amendments to the current Articles, are available for inspection as noted in paragraph 15 of the Notes to the Notice of Annual General Meeting below and are also available on the Company's website, www.allergytherapeutics.com.

Recommendation

Your Directors believe that the above proposals are in the best interests of the Company and its shareholders as a whole and unanimously recommend that shareholders vote in favour of all the resolutions, as the Directors intend to do in respect of their own beneficial shareholdings, totalling 9,167,707 shares, representing approximately 0.15% of the issued share capital of the Company as at 2 January 2026, being the last practicable date before posting of this document.

Yours sincerely

Peter Jensen O.B.E.

Chairman

Notice of Annual General Meeting

Notice is hereby given that the annual general meeting (the "AGM") of Allergy Therapeutics plc (the "Company") will be held at the offices of Cooley (UK) LLP at 22 Bishopsgate, London EC2N 4BQ on 29 January 2026 at 11:00 a.m..

You will be asked to consider and vote on the resolutions below. Resolutions 1 to 10 will be proposed as ordinary resolutions and Resolutions 11 to 13 will be proposed as special resolutions.

Ordinary Resolutions:

1. To receive the Directors' report, the consolidated financial statements and the auditors' report of the Company for the year ended 30 June 2025 (the "2025 Accounts").
2. To approve the Directors' remuneration report, as set out on pages 55 to 62 of the 2025 Accounts.
3. To elect as a Director of the Company Helge Weiner-Trapness pursuant to article 69.
4. To elect as a Director of the Company Lawrence Allen Wang pursuant to article 69.
5. To re-elect as a Director of the Company Tunde Otlulana who retires by rotation and offers himself for re-election pursuant to article 73.
6. To re-elect as a Director of the Company Cheryl MacDiarmid who retires by rotation and offers herself for re-election pursuant to article 73.
7. To re-elect as a Director of the Company Peter Jensen O.B.E. who has served more than nine years on the Board and therefore retires and offers himself for re-election.
8. To re-appoint BDO LLP as auditors of the Company to hold office from conclusion of this AGM until the conclusion of the next annual general meeting of the Company at which accounts are laid before the Company.
9. To authorise the Directors to agree the auditors' remuneration.
10. THAT, the Directors be and they are hereby generally and unconditionally authorised and empowered in accordance with section 551 of the Companies Act 2006 (the "Companies Act") to exercise all the powers of the Company to allot shares in the Company and to grant rights to subscribe for or to convert any security into shares in the Company:
 - 10.1. up to an aggregate nominal amount of £2,250,480; and
 - 10.2. comprising equity securities (as defined in section 560 of the Companies Act) up to an aggregate nominal amount of £4,500,960 (including within such limit any shares and rights to subscribe for or convert any security into shares allotted or granted under sub-paragraph 10.1 above) in connection with or pursuant to a pre-emptive offer:
 - (i) to ordinary shareholders in proportion (as nearly as may be practicable) to the respective number of ordinary shares held by them on the record date for such allotment; and
 - (ii) to holders of other equity securities as required by the rights of those securities or as the Directors otherwise consider necessary,

and so that the Directors may impose any limits or restrictions and make any arrangements which they consider necessary or expedient to deal with treasury shares, fractional entitlements, record dates, or legal, regulatory or practical problems in, or under the laws of any territory or the requirements of a regulatory body or stock exchange or

any other matter, provided that these authorities shall expire on the earlier of the conclusion of the next annual general meeting of the Company or 16 March 2027 (unless and to the extent that such authorities are renewed or extended prior to such date), save that the Company may before such expiry make an offer or agreement which would or might require shares to be allotted or rights to be granted after such expiry and the Directors may allot shares or grant rights to subscribe for or to convert any security into shares in pursuance of such offer or agreement as if the authorities conferred hereby had not expired.

This power shall be in addition to all subsisting powers previously given to the Directors for the purposes of section 551 of the Companies Act, which shall continue in full force and effect.

Special Resolutions:

11. THAT, subject to the passing of Resolution 10, the Directors be authorised to allot equity securities (as defined in the Companies Act) for cash under the authority given by that resolution and/or to sell ordinary shares held by the Company as treasury shares for cash as if section 561 of the Companies Act 2006 did not apply to any such allotment or sale, such authority to be limited to:
 - 11.1. the allotment of equity securities in connection with an offer of or invitation to acquire equity securities (but in the case of the authority granted under sub-paragraph 10.2 by way of a pre-emptive offer only):
 - (i) to ordinary shareholders in proportion (as nearly as may be practicable) to the respective number of ordinary shares held by them on the record date for such allotment; and
 - (ii) to holders of other equity securities, as required by the rights of those securities, or as the Directors otherwise consider necessary,
- but subject to such exclusions or other arrangements as the Directors may deem necessary or appropriate to deal with treasury shares, fractional entitlements, record dates, or legal, regulatory or practical problems in, or under the laws of any territory or the requirements of a regulatory body or stock exchange or any other matter;
- 11.2. the allotment of equity securities or sale of treasury shares (otherwise than under sub-paragraph 11.1 above) having a nominal amount not exceeding in aggregate £675,144; and
- 11.3. to the allotment of equity securities or sale of treasury shares (otherwise than under sub-paragraph 11.1 or sub-paragraph 11.2 above) up to a nominal amount equal to 20% of any allotment of equity securities or sale of treasury shares from time to time under sub-paragraph 11.2 above, such authority to be used only for the purposes of making a follow-on offer which the Board of the Company determines to be of a kind contemplated by paragraph 3 of Section 2B of the Statement of Principles on Disappling Pre-Emption Rights most recently published by the Pre-Emption Group prior to the date of this notice of AGM, such authority to expire at the conclusion of the next annual general meeting of the Company or, if earlier, 16 March 2027 (unless and to the extent that such authority is renewed or extended prior to such date), but, in each case, prior to its expiry the Company may make offers, and enter into agreements, which would, or might, require equity securities to be allotted (and treasury

shares to be sold) after the authority expires and the Board may allot equity securities (and sell treasury shares) under any such offer or agreement as if the authority had not expired.

This power shall be in addition to all subsisting powers previously given to the Directors for the purposes of section 570 of the Companies Act, which shall continue in full force and effect.

12. That, subject to the passing of Resolution 10, the Directors be authorised in addition to any authority granted under Resolution 11 to allot equity securities (as defined in the Companies Act) for cash under the authority given by that resolution and/or to sell ordinary shares held by the Company as treasury shares for cash as if section 561 of the Companies Act did not apply to any such allotment or sale, such authority to be limited to:

- 12.1. the allotment of equity securities or sale of treasury shares up to a nominal amount of £675,144, such authority to be used only for the purposes of financing (or refinancing, if the authority is to be used within 12 months after the original transaction) a transaction which the Board of the Company determines to be either an acquisition or a specified capital investment of a kind contemplated by the Statement of Principles on Disapplying Pre-Emption Rights most recently published by the Pre-Emption Group prior to the date of this notice of AGM; and
 - 12.2. the allotment of equity securities or sale of treasury shares (otherwise than under sub-paragraph 12.1 above) up to a nominal amount equal to 20% of any allotment of equity securities or sale of treasury shares from time to time under sub-paragraph 12.1 above, such authority to be used only for the purposes of making a follow-on offer which the Board of the Company determines to be of a kind contemplated by paragraph 3 of Section 2B of the Statement of Principles on Disapplying Pre-Emption Rights most recently published by the Pre-Emption Group prior to the date of this notice of AGM, such authority to expire at the conclusion of the next annual general meeting of the Company or, if earlier, 16 March 2027 (unless and to the extent that such authority is renewed or extended prior to such date), but, in each case, prior to its expiry the Company may make offers, and enter into agreements, which would, or might, require equity securities to be allotted (and treasury shares to be sold) after the authority expires and the Board may allot equity securities (and sell treasury shares) under any such offer or agreement as if the authority had not expired.

This power shall be in addition to all subsisting powers previously given to the Directors for the purposes of section 570 of the Companies Act, which shall continue in full force and effect.

13. THAT with effect from the conclusion of the meeting the draft articles of association produced to the meeting and, for the purposes of identification, initialled by the Chairman be adopted as the articles of association of the Company in substitution for, and to the exclusion of, the Company's existing articles of association.

By Order of the Board

Karley Cheesman

Company Secretary

Allergy Therapeutics plc

Dominion Way

Worthing

West Sussex

BN14 8SA

6 January 2026

Notes to the Notice of Annual General Meeting

1. Only those members registered on the Company's register of members at:
 - (i) 6:00 p.m. on 27 January 2026; or,
 - (ii) if this AGM is adjourned, at close of business on the day two days prior to the adjourned meeting,shall be entitled to attend and vote at the AGM.
2. Persons intending to attend the AGM in person will need a QR code to access the meeting venue. Such QR code will need to be displayed on a smartphone or similar device. A QR code will be able to be obtained in advance by emailing the Registrars, MUFG Corporate Markets, at meetingsadvisoryteam@cm.mpms.mufg.com with your full name and email address. Persons who have not obtained a QR code in advance will be able to obtain one at the meeting venue.
3. If you are a member of the Company who is entitled to attend and vote at the AGM, you are entitled to appoint a proxy to exercise all or any of your rights to attend, speak and vote at the AGM. A proxy does not need to be a member of the Company but must attend the AGM to represent you.
As noted in the Chairman's letter, you are urged to appoint the chair of the AGM as your proxy, with voting instructions, in advance of the AGM.
4. A proxy form can be requested from the registrar MUFG Corporate Markets whose contact details are provided in note 16. To appoint a proxy using the proxy form, the form must be:
 - (i) completed and signed;
 - (ii) sent to the Company's Registrars, MUFG Corporate Markets at PXS1, Central Square, 29 Wellington Street, Leeds LS1 4DL; and
 - (iii) received by the Company's Registrars no later than 11:00 a.m. on 27 January 2026.

In the case of a member which is a company, the proxy form must be executed under its common seal or signed on its behalf by an officer of the company or an attorney for the company. Any power of attorney or any other authority under which the proxy form is signed (or a duly certified copy of such power or authority) must be included with the proxy form.

You may appoint more than one proxy provided each proxy is appointed to exercise rights attached to different shares. You may not appoint more than one proxy to exercise rights attached to any one share. To appoint more than one proxy, please contact the Company's Registrars, whose details can be found in note 16 below.

5. Shareholders can vote electronically via the Investor Centre. It is a free app for smartphone and tablet provided by MUFG Corporate Markets (the company's registrar). It allows you to securely manage and monitor your shareholdings in real time, take part in online voting, keep your details up to date, access a range of information including payment history and much more. The app is available to download on both the Apple App Store and Google Play, or by scanning the relevant QR code below.



Alternatively, you may access the Investor Centre via a web browser at: <https://uk.investorcentre.mpms.mufg.com/>.

6. CREST members who wish to appoint a proxy or proxies by utilising the CREST electronic proxy appointment service may do so for the AGM and any adjournment(s) of it by using the procedures described in the CREST Manual (available from www.euroclear.com). CREST Personal Members or other CREST sponsored members, and those CREST members who have appointed a voting service provider(s), should refer to their CREST sponsor or voting service provider(s), who will be able to take the appropriate action on their behalf.

In order for a proxy appointment made by means of CREST to be valid, the appropriate CREST message (a CREST Proxy Instruction) must be properly authenticated in accordance with Euroclear UK & International Limited's ("Euroclear") specifications and must contain the information required for such instructions, as described in the CREST Manual. The message must be transmitted so as to be received by the issuer's agent (ID RA10) by no later than 48 hours before the time appointed for the AGM. For this purpose, the time of receipt will be taken to be the time (as determined by the time stamp applied to the message by the CREST Applications Host) from which the issuer's agent is able to retrieve the message by enquiry to CREST in the manner prescribed by CREST.

CREST members and, where applicable, their CREST sponsors or voting service providers should note that Euroclear does not make available special procedures in CREST for any particular messages. Normal system timings and limitations will therefore apply in relation to the input of CREST Proxy Instructions. It is the responsibility of the CREST member concerned to take (or, if the CREST member is a CREST personal member or sponsored member or has appointed a voting service provider(s), to procure that his CREST sponsor or voting service provider(s) take(s)) such action as shall be necessary to ensure that a message is transmitted by means of the CREST system by any particular time. In this connection, CREST members and, where applicable, their CREST sponsors or voting service providers are referred, in particular, to those sections of the CREST Manual concerning practical limitations of the CREST system and timings.

The Company may treat as invalid a CREST Proxy Instruction in the circumstances set out in Regulation 35(5)(a) of the Uncertificated Securities Regulations 2001.
7. In the case of joint holders, where more than one of the joint holders purports to appoint a proxy, only the appointment submitted by the most senior holder will be accepted. Seniority is determined by the order in which the names of the joint holders appear in the Company's register of members in respect of the joint holding (the first-named being the most senior).
8. To change your proxy instructions simply submit a new proxy appointment using the methods set out above. Note that the cut-off time for receipt of proxy appointments (see above) also applies in relation to amended instructions; any amended proxy appointment received after the relevant cut-off time will be disregarded. Where you have appointed a proxy using the hard-copy proxy form and would like to change the instructions using another hard-copy proxy form, please contact Company's Registrars whose details can be found in note 16 below. If you submit more than one valid proxy appointment, the appointment received last before the latest time for the receipt of proxies will take precedence.

9. Appointment of a proxy does not preclude you from attending the AGM and voting in person.
10. A corporation which is a member can appoint one or more corporate representatives who may exercise, on its behalf, all its powers as a member provided that no more than one corporate representative exercises powers over the same share.
11. Unless otherwise indicated on proxy form, the CREST Proxy Instruction, electronic voting instruction via the Investor Centre or other proxy appointment, the proxy will vote as they think fit or, at their discretion or withhold from voting.
12. As at 6:00 p.m. on 2 January 2026 the Company's issued share capital comprised 6,141,439,951 ordinary shares of 0.1 pence each. Each ordinary share carries the right to one vote at a general meeting of the Company and, therefore, the total number of voting rights in the Company as at 6:00 p.m. on 2 January 2026 is 6,141,439,951.
13. Voting on all resolutions will be conducted by way of a poll.
14. Under Section 527 of the Companies Act, shareholders meeting the threshold requirements set out in that section have the right to require the Company to publish on a website a statement setting out any matter relating to: (i) the audit of the Company's financial statements (including the auditor's report and the conduct of the audit) that are to be laid before the AGM; or (ii) any circumstances connected with an auditor of the Company ceasing to hold office since the previous meeting at which annual financial statements and reports were laid in accordance with Section 437 of the Companies Act (in each case) that the shareholders propose to raise at the relevant meeting. The Company may not require the shareholders requesting any such website publication to pay its expenses in complying with sections 527 or 528 of the Companies Act. Where the Company is required to place a statement on a website under section 527 of the Companies Act, it must forward the statement to the Company's auditor not later than the time when it makes the statement available on the website. The business which may be dealt with at the AGM for the relevant financial year includes any statement that the Company has been required under section 527 of the Companies Act to publish on a website.
15. The following documents will be available for inspection at the registered office of the Company during normal business hours until the end of the AGM:
 - (i) the Amended Articles;
 - (ii) copies of the service contracts of Executive Directors of the Company; and
 - (iii) copies of the letters of appointment of the Non-Executive Directors of the Company.
16. Members who have general queries about the AGM should contact the Company's Registrars, MUFG Corporate Markets, Central Square, 29 Wellington Street, Leeds LS1 4DL. Shareholders can email shareholderenquiries@cm.mmps.mufg.com or call the registrar on 0371 664 0300 or, if calling from overseas, on +44 371 664 0300. Calls are charged at the standard geographic rate and will vary by provider. Calls from outside the United Kingdom will be charged at the applicable international rate. Lines are open between 9.00 a.m. and 5:30 p.m. (London time), Monday to Friday excluding public holidays in England and Wales.
17. You may not use any electronic address provided either:
 - (i) in this notice of AGM; or
 - (ii) any related documents (including the proxy form), to communicate with the Company for any purposes other than those expressly stated.



Dominion Way
Worthing
West Sussex
BN14 8SA

www.allergytherapeutics.com